Maximum quantity allowed is 999
Please select the quantity
CAS RN: 154361-50-9 | Product Number: C2878
Capecitabine
![Capecitabine No-Image](/medias/C2878.jpg?context=bWFzdGVyfHJvb3R8NTIwODJ8aW1hZ2UvanBlZ3xhR1JpTDJnNU5pODRPVEl3TnpZM09USXlNakEyTDBNeU9EYzRMbXB3Wnd8NGQxMjA0MmJkZTAzMjE2YmI4ZWVjNGE4ZjhiNjk1Yjc1YWFkNTcwMjg4NTRlMDc4ZTdlMzlhMDk5NGU0YjAzNA)
Purity: >98.0%(T)(HPLC)
Synonyms:
- 5'-Deoxy-5-fluoro-N4-[(pentyloxy)carbonyl]cytidine
Product Documents:
Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
![]() |
---|---|---|---|---|---|
1G |
NT$4,560
|
1 | 0 | Contact Us | |
5G |
NT$15,720
|
≥60 | ≥80 | Contact Us |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
Product Number | C2878 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__1__5H__2__2FN__3O__6 = 359.35 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Heat Sensitive |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
CAS RN | 154361-50-9 |
Reaxys Registry Number | 8583270 |
PubChem Substance ID | 253661933 |
Merck Index (14) | 1754 |
MDL Number | MFCD00930626 |
Specifications
Appearance | White to Almost white powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Neutralization titration) | min. 98.0 % |
Specific rotation [a]20/D | +96.0 to +100.0 deg(C=1, MeOH) |
Properties (reference)
Melting Point | 123 °C(dec.) |
Specific Rotation | 98° (C=1,MeOH) |
Solubility in water | Slightly soluble |
Degree of solubility in water | 26 g/l 20 °C |
GHS
Pictogram |
![]() ![]() |
Signal Word | Danger |
Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
RTECS# | HA3852500 |
Transport Information:
H.S.code* | 2934.99-000 |
Application
Capecitabine: A Prodrug of 5-fluorouracil (5-FU) [F0151] for Selective Delivery to Tumor
Capecitabine is a prodrug of antitumor antimetabolite, metabolized to the active form 5-fluorouracil (5-FU) [F0151] by three enzymes located in the liver and in tumors. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine [D4342] and 5'-deoxy-5-fluorouridine (doxifluridine) [D3579], to form 5-FU. Capecitabine and its intermediary metabolites are not cytotoxic by themselves. The final step (doxifluridine to 5-FU) requires thymidine phosphorylase (dThdPase) that is significantly more active in tumor than normal tissue. This tumor-selective delivery of 5-FU ensured greater efficacy and a more favorable safety profile than with other fluoropyrimidines. For your reference, [D5787] is a synthetic precursor of capecitabine. (The product is for research purpose only.)
References
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
- Capecitabine: preclinical pharmacology studies (a review)
- Clinical pharmacokinetics of capecitabine (a review)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Capecitabine: an overview of the side effects and their management (a review)
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.